YCYou-Jung Choi

You-Jung Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


You-Jung Choi has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis

    by Meraj Neyazi, Gabriela Venturini, Kemar J. Brown, Youjung Choi, Joshua M. Gorham, Olivia G. Layton, Arjun Verma, Adam J. Wang, Ryan T. Gross, Barbara A. McDonough, et al.

    BACKGROUND: Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions without granuloma. CS causes arrhythmias, sudden cardiac death, and heart failure. The mechanisms producing this remarkable histopathology and disease progression remain unexplained. METHODS: Using comprehensive single-cell and spatial transcriptomic analyses, we characterized the cellular composition and gene expression in preserved, granulomatous, and fibrotic regions of human CS hearts. From unexpectedly identified clonally expanded cardiac B cells with rearranged immunoglobulin sequences, we reconstructed antibodies and screened libraries comprising the human peptidome or microbial and allergen peptides to define reactive epitopes in CS hearts. RESULTS: Cellular composition and gene expression differed substantially in CS tissues with preserved, granulomatous, or fibrotic histopathology. Cardiomyocytes upregulated arrhythmogenic and inflammasome transcripts associated with pyroptosis. Cardiomyocytes and fibroblasts activated chemoattractant cytokines that sustained myeloid and lymphoid infiltration. Granulomas contained abundant macrophages expressing modulators of cell–cell fusion, along with Th17-skewed T cells that upregulated B-cell–activating factor, thereby promoting antibody production. Fibrotic regions, without active granulomas, exhibited tertiary lymphoid structures, with clonal expansion of mature B and plasma cells. Reconstructed antibodies derived from expanded B-cell clones were inert to microbial and allergen peptides, but reacted to PPL (periplakin), a desmosome protein, and other peptides expressed on cardiac cells. CONCLUSIONS: Progressive inflammatory signals in CS are mediated by chemoattractant genes in cardiomyocytes and fibroblasts within preserved myocardium, cell–cell fusion modulators in activated macrophages within granulomatous regions, and tertiary lymphoid structures in fibrotic regions that produce patient-specific autoimmune antibodies. Identification of PPL as a CS autoantigen may account for shared clinical manifestations in CS and arrhythmic desmosomal cardiomyopathies. CS autoantigens may underlie enigmatic histopathologic findings, perpetuate disease, and contribute to adverse outcomes. Uncovering an intracardiac humoral autoimmune axis in CS provides specific therapeutic opportunities to limit granuloma formation and B-cell activation, which may reduce arrhythmogenicity and progressive dysfunction. Parallel analytic strategies have potential to define autoantigens in other enigmatic cardiac immune disorders.


  • Cardiovascular risk in women with metabolic dysfunction-associated steatotic liver disease across the menopausal transition

    by You-Jung Choi, Sungho Bea, Sung Won Chung, Ho-Tack Seo, Tae Min Rhee, Chan Soon Park, Heesun Lee, Kyung-Do Han, Yong Jin Kim, Hyung Kwan Kim, et al.

    Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a substantial global health burden, yet the cardiovascular impact across menopausal status remains unclear. Thus, this study aimed to assess the association between MASLD and cardiovascular risk in premenopausal and postmenopausal women. Methods and results: We conducted a nationwide population-based cohort study using the Korean National Health Insurance Service database. Women aged 40 years or older were categorized by the fatty liver index as having no MASLD (<30), grade 1 (30–59), or grade 2 (≥60). The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischaemic stroke, and cardiovascular death. Among 1 931 330 women aged 40 years or older, including 837 363 premenopausal and 1 093 967 postmenopausal women, MACE incidence (per 1000 person-years) increased with MASLD severity: 1.82, 2.93, and 3.91 in premenopausal women, and 7.68, 10.55, and 12.36 in postmenopausal women. 5-year absolute MACE risks also rose with MASLD severity: premenopausal (0.45% [95% CI 0.44–0.47%], 0.65% [95% CI 0.62–0.68%], 0.87% [95% CI 0.82–0.93%]) and postmenopausal (2.74% [95% CI 2.71–2.77%], 3.25% [95% CI 3.20–3.30%], 3.83% [95% CI 3.75–3.91%]). Absolute risk differences between no MASLD and grades 1 or 2 were over twice as large in postmenopausal women (0.51% [95% CI 0.47–0.55%] and 1.09% [95% CI 1.02–1.17%]) than in premenopausal women (0.20% [95% CI 0.17–0.22%] and 0.42% [95% CI 0.37–0.47%]). Conclusion: MASLD was associated with increased cardiovascular risk in both premenopausal and postmenopausal women. The absolute excess risk associated with MASLD was larger in postmenopausal women. These findings emphasize incorporating hepatic steatosis severity and menopausal status into cardiovascular risk assessment and prevention strategies for women’s health.


  • Open Access

    Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy

    by You-Jung Choi, Neal K. Lakdawala

    Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), conferring a markedly increased risk of thromboembolic events. Conventional risk stratification tools such as the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74 years, female sex) score are often insufficient to predict thromboembolic events in patients with HCM and AF, as thromboembolic risk in HCM is driven by disease-specific structural, functional, and prothrombotic substrates. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, and clinical impact of AF and thromboembolism in HCM. We discuss variable imaging modalities—including strain echocardiography, cardiac magnetic resonance, and cardiac computed tomography—that offer enhanced characterization of atrial remodeling and thromboembolic risk in patients with HCM. Furthermore, we outline current guideline-based anticoagulation strategies, the evolving role of direct oral anticoagulants, and adjunctive therapies such as left atrial appendage occlusion and catheter ablation. A comprehensive, multidisciplinary approach that incorporates advanced imaging, molecular profiling, and individualized management is ideal to optimize outcomes and reduce stroke burden in patients with HCM and AF.


  • Open Access

    Association of Handgrip Strength With Readmission, Mortality, and Exercise Capacity in Patients With Heart Failure

    by Soohyung Park, Se Hyun Park, Jieun Lee, You-Jung Choi, Dong Oh Kang, Eun Jin Park, Jah Yeon Choi, Seung-Young Roh, Dae-In Lee, Jin Oh Na, et al.

    Background: Patients with heart failure (HF) experience a marked reduction in overall skeletal muscle strength and exercise capacity, which is detrimental to their prognosis. This study examined the clinical implications of handgrip strength (HGS) in patients with HF. Methods: Overall, 173 patients (mean age, 62 years; 81.5% male) underwent cardiac rehabilitation from 2015 to 2020. Baseline HGS was measured as the average value (kg) for both hands using a handheld dynamometer. For each patient, distance walked during a 6-min walk test and metabolic equivalents were recorded. The primary outcome was the composite of readmissions for HF and all-cause death. Results: Receiver operating characteristic curve for the primary outcome revealed 24.9 kg as the HGS cutoff point (area under curve: 0.702, 95% confidence interval [0.610, 0.794], p < .001) and multivariable Cox proportional hazard analysis revealed that lower HGS was significantly associated with a higher risk of readmission for HF or all-cause death (hazard ratio [HR] 6.44, 95% confidence interval [2.86, 14.50], p < .001). This result is mainly attributed to the increased risk of readmission for HF in this group (hazard ratio 6.75, 95% confidence interval [2.87, 15.88], p < .001). Moreover, HGS was significantly positively correlated with distance on 6-min walk test (r = .564, p < .001) and metabolic equivalents (r = .419, p < .001), and is one of the strongest predictors of each exercise capacity category. Conclusions: As our findings suggested, HGS is an indicator of exercise capacity and a useful marker for predicting hospital readmission or all-cause death in patients with HF.


  • Open Access

    Evaluation of Burnout and Contributing Factors in Imaging Cardiologists in Korea

    by You-Jung Choi, Kang-Un Choi, Young-Mee Lee, Hyun-Jung Lee, Inki Moon, Jiwon Seo, Kyu Kim, So Ree Kim, Jihoon Kim, Hong-Mi Choi, et al.

    Choi YJ, et al. J Korean Med Sci. 2024 Nov;40:e21. https://doi.org/10.3346/jkms.2025.40.e21


  • Open Access

    Early Versus Late Initiation of Warfarin Post-Cesarean Section: A Step Forward in Managing Mechanical Heart Valve Patients

    by You-Jung Choi

    Choi YJ. Korean Circ J. 2024 Jul;54:e97. https://doi.org/10.4070/kcj.2024.0228

  • Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis

    by You-Jung Choi, Jah Yeon Choi, Jieun Lee, Byoung Geol Choi, Soohyung Park, Dong Oh Kang, Eun Jin Park, Ji Bak Kim, Seung-Young Roh, Cheol Ung Choi, et al.

    BACKGROUND: Current guidelines recommend intervention for asymptomatic rheumatic mitral stenosis (MS) with mitral valve area ≤1.5 cm 2 based on indicators including pulmonary arterial systolic pressure (PASP) >50 mm Hg and new-onset atrial fibrillation; however, evidence supporting this is lacking. METHODS: This single-center retrospective study included patients with rheumatic MS between 2006 and 2022. Pulmonary hypertension was evaluated by using echocardiography to estimate PASP. Primary outcomes were major adverse cardiovascular events (MACE), including all-cause mortality, hospitalization for heart failure, and arterial thromboembolic events for up to 5 years. RESULTS: Overall, 287 patients with severe rheumatic MS were enrolled (mean age, 62.5±11.3 years; 74.6% women). During a median follow-up of 2.52 years, MACE occurred in 99 patients. There were no differences in echocardiographic parameters, such as the mean mitral valve pressure gradient, mitral valve area, and proportion of mitral valve area 50 mm Hg than in those with ePASP ≤50 mm Hg (log-rank P P 45 mm Hg, which was an independent predictor of MACE in patients with severe rheumatic MS (adjusted hazard ratio, 2.127 [95% CI, 1.424–3.177]; P 45 mm Hg) as a predictor of an unfavorable prognosis.


  • Open Access

    Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years

    by You-Jung Choi, Yun Jin Choi, Ji Eun Lee, Jah Yeon Choi, Geum Joon Cho, Jin Oh Na

    OBJECTIVES: This study investigated the prevalence, incidence, and prognosis of cardiac amyloidosis (CA) in Korea.METHODS: This retrospective nationwide population-based study used the Health Insurance Review and Assessment Service databases between 2008 and 2020. All patients diagnosed with amyloidosis were included, and those with a diagnosis of heart failure or cardiomyopathy were classified as having CA. Both the special code for amyloidosis (V121), which enables coverage of medical expenses, and the corresponding International Classification of Diseases, 10th revision codes for amyloidosis (E850- E854, E858, E859) were used to improve the reliability of amyloidosis diagnosis.RESULTS: Among 2,239 patients with amyloidosis, 758 met the criteria for CA (mean age, 64.4±11.9 years; 59.1% male). The mean age of patients with CA increased from 59.5±14.7 years in 2009 to 68.1±13.9 years in 2020. The incidence and prevalence increased from 0.09 (95% confidence interval [CI], 0.06 to 0.12) to 0.22 (95% CI, 0.18 to 0.27) per 100,000 person-years and 0.20 (95% CI, 0.16 to 0.25) to 1.30 (95% CI, 0.12 to 0.42) per 100,000 persons, respectively (all p<0.001). Patients with light-chain CA showed similar trends. In-hospital mortality decreased from 17.3% (95% CI, 9.23 to 29.6) to 6.10% (95% CI, 4.21 to 8.48) between 2009 and 2020. While age-specific in-hospital mortality was significantly higher in patients aged ≥70 years (p=0.004), no significant age-specific difference in in-hospital mortality was observed in patients with CA aged <70 years (p=0.981).CONCLUSIONS: The prevalence and incidence of CA have increased in Korea, predominantly affecting older individuals, particularly males. Notably, in-hospital mortality decreased significantly.


  • Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study

    by You-Jung Choi, Jaehyun Lim, Sungho Bea, Jieun Lee, Jah Yeon Choi, Seung Young Rho, Dae-In Lee, Jin Oh Na, Hyung-Kwan Kim

    Background and Aims: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0–21 days following COVID-19 vaccination. Results: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77–1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39–2.54) following vaccination. Conclusions: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.


  • Open Access

    Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort

    by Jaehyun Lim, Soongu Kwak, You‐Jung Choi, Tae‐Min Rhee, Chan Soon Park, Bongseong Kim, Kyung‐Do Han, Heesun Lee, Jun‐Bean Park, Yong‐Jin Kim, et al.

    Background: Meta‐analyses of large clinical trials investigating SGLT2 (sodium‐glucose cotransporter‐2) inhibitors have suggested their protective effects against atrial fibrillation in patients with type 2 diabetes. However, the results were predominantly driven from trials involving dapagliflozin. Methods and Results: We used a nationwide, population‐based cohort of patients with type 2 diabetes who initiated either dapagliflozin or empagliflozin between May 2016 and December 2018. An active‐comparator, new‐user design was used, and the 2 groups of patients were matched using propensity scores. The primary outcome was incident nonvalvular atrial fibrillation, which was analyzed using both the main intention‐to‐treat and sensitivity analysis that censored patients who skipped their medications for ≥30 days. Men ≥55 years of age and women ≥60 years of age with ≥1 traditional risk factor or those with established cardiovascular disease were categorized as high cardiovascular risk group. Patients not included in the high‐risk group were categorized as low risk. After 1:1 propensity‐score matching, a total of 137 928 patients (mean age, 55 years; 58% men) were included and followed up for 2.2±0.6 years. The risk of incident atrial fibrillation was significantly lower in the dapagliflozin group in both the main (hazard ratio [HR], 0.885 [95% CI, 0.789–0.992]) and sensitivity analyses (HR, 0.835 [95% CI, 0.719–0.970]). Notably, this was consistent in both the low and high cardiovascular risk groups. There was no effect modification by age, sex, body mass index, duration of diabetes, or renal function. Conclusions: This real‐world, population‐based study demonstrates that patients with type 2 diabetes using dapagliflozin may have a lower risk of developing nonvalvular atrial fibrillation than those using empagliflozin.